TAM
CYCN icon

Tyers Asset Management’s Cyclerion Therapeutics CYCN Stock Holding History

Tyers Asset Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$14K Hold
56
– – ﹤0.01% 973
2019
Q2 		$13K Buy
+56
New +$15.8K ﹤0.01% 973

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Tyers Asset Management's CYCN Position: Q3 2019 in Review

Tyers Asset Management held its Cyclerion Therapeutics (CYCN) position steady in Q3 2019 at 56 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #973.

Tyers Asset Management first reported a position in CYCN in Q2 2019 and has held it in 2 quarters since. 90 funds tracked by Wall St. Rank hold CYCN as of Q3 2019.

  • Tyers Asset Management held 56 shares of Cyclerion Therapeutics worth $14K as of Q3 2019.
  • Tyers Asset Management left its Cyclerion Therapeutics share count unchanged in Q3 2019.
  • Cyclerion Therapeutics made up ﹤0.01% of Tyers Asset Management's portfolio in Q3 2019, its #973 holding.
  • Tyers Asset Management first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 2 quarters since.
  • 90 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2019.

Based on Tyers Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.